Uroxatral en es it fr

Uroxatral Brand names, Uroxatral Analogs

Uroxatral Brand Names Mixture

  • No information avaliable

Uroxatral Chemical_Formula


Uroxatral RX_link


Uroxatral fda sheet

Uroxatral FDA

Uroxatral msds (material safety sheet)

Uroxatral Synthesis Reference

No information avaliable

Uroxatral Molecular Weight

389.449 g/mol

Uroxatral Melting Point

No information avaliable

Uroxatral H2O Solubility

No information avaliable

Uroxatral State


Uroxatral LogP


Uroxatral Dosage Forms

Tablet (extended-release)

Uroxatral Indication

For the treatment of the signs and symptoms of benign prostatic hyperplasia.

Uroxatral Pharmacology

Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity.

Uroxatral Absorption

Absorption is 50% lower under fasting conditions

Uroxatral side effects and Toxicity

side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.

Uroxatral Patient Information


Follow the links




Uroxatral Organisms Affected

Humans and other mammals